Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19364297 | FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION | October 2025 | March 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 19350804 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | October 2025 | January 2026 | Allow | 3 | 1 | 0 | No | No |
| 19350928 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | October 2025 | January 2026 | Allow | 3 | 1 | 0 | No | No |
| 19333265 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19322628 | CAPSID VARIANTS AND METHODS OF USING THE SAME | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19294594 | VARIANT STRAIN-BASED CORONAVIRUS VACCINES | August 2025 | March 2026 | Allow | 7 | 1 | 1 | Yes | No |
| 19282553 | PLANT COLONIZATION ASSAYS USING NATURAL MICROBIAL BARCODES | July 2025 | March 2026 | Allow | 8 | 1 | 0 | No | No |
| 19279954 | SYSTEMS, METHODS AND COMPOSITIONS FOR ANALYSIS OF PROTEOFORMS | July 2025 | March 2026 | Allow | 7 | 1 | 1 | No | No |
| 19278342 | IL-23 ANTIBODY COMPOSITIONS AND METHODS OF USE | July 2025 | December 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19267411 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | July 2025 | August 2025 | Allow | 1 | 0 | 0 | No | No |
| 19262172 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | July 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19252926 | BCMA x CD3 T BISPECIFIC CELL ENGAGER | June 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19251906 | ANTI-CD79B PROTEIN MONOCLONAL ANTIBODY, PRODUCTS CONTAINING THE SAME, AND USES THEREOF | June 2025 | September 2025 | Allow | 3 | 0 | 0 | No | No |
| 19252441 | ANTI-TREM2 AGONIST ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF THAT CAN INCREASE LEVELS OF SOLUBLE TREM2 IN SERUM AND BRAIN TISSUE | June 2025 | November 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 19246586 | FUSION ANTIGEN OF PORCINE GETAH VIRUS, KIT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | June 2025 | December 2025 | Allow | 6 | 1 | 0 | No | No |
| 19229610 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | June 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19209867 | ANTI-CD8 ALPHA DEPLETING ANTIBODIES | May 2025 | September 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 19209113 | CAPSID VARIANTS AND METHODS OF USING THE SAME | May 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 19204075 | NUCLEIC ACID MOLECULES AND USES THEREOF | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19203759 | SYSTEM FOR PRODUCING AND DELIVERING CONTACTLESS VETERINARY PASSIVE IMMUNIZATION | May 2025 | November 2025 | Allow | 6 | 1 | 1 | No | No |
| 19199750 | METHODS AND DEVICES FROM ISOLATION OF TUMOR CELLS | May 2025 | January 2026 | Allow | 9 | 1 | 1 | Yes | No |
| 19194993 | ALLOGENEIC HUMAN PLASMA AND PLATELET DERIVED PRODUCTS AND USES THEREOF | April 2025 | December 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19192233 | Oral Dosing of GLP-1 Compounds | April 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 19183257 | SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES | April 2025 | November 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19182727 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | April 2025 | October 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19182766 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | April 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19178522 | BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 19171004 | METHODS FOR PERFORMING MINIATURIZED DYNAMIC ASSAYS USING MICROFLUIDICS AND RELATED SYSTEMS | April 2025 | February 2026 | Allow | 10 | 1 | 1 | No | No |
| 19092603 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | March 2025 | January 2026 | Allow | 10 | 2 | 0 | No | No |
| 19091651 | Methods of Detecting, Identifying and Quantifying Wild Spike Protein and Covid Vaccine Spike Proteins | March 2025 | November 2025 | Allow | 8 | 2 | 0 | No | No |
| 19091464 | NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | March 2025 | February 2026 | Allow | 11 | 2 | 0 | Yes | No |
| 19088722 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19088718 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19088729 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | March 2025 | November 2025 | Allow | 8 | 1 | 0 | No | No |
| 19087398 | HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS | March 2025 | August 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19084523 | A COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USES | March 2025 | October 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 19079771 | PROTEIN-ENCLOSING POLYMERIC MICELLE | March 2025 | February 2026 | Allow | 11 | 1 | 0 | No | No |
| 19077147 | ANTIBIOTIC FREE TREATMENT OF MASTITIS | March 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19075180 | COMPOSITIONS AND METHODS | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19073950 | METHODS OF ASSAYING PHOSPHORYLATED TAU PROTEIN IN A SAMPLE | March 2025 | December 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 19067863 | Phage Composition and Its Use in Strengthening Soil Carbon Fixation | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 19067426 | SELF-ASSEMBLING NANOPARTICLES | February 2025 | January 2026 | Allow | 11 | 1 | 1 | Yes | No |
| 19064136 | METHODS FOR THE TREATMENT OF MELANOMA USING COMPOSITIONS OF DENOSUMAB AND PD-1 INHIBITOR | February 2025 | December 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 19062335 | MULTI-DOSE PEN OF TIRZEPATIDE | February 2025 | December 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19061831 | METHODS OF TREATING INFLAMMATORY ARTHRITIS USING IL-17 ANTAGONISTS | February 2025 | January 2026 | Allow | 11 | 2 | 1 | Yes | No |
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19056312 | PD1 AND VEGFR2 DUAL-BINDING AGENTS | February 2025 | October 2025 | Allow | 8 | 1 | 1 | No | No |
| 19053784 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19053808 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19052822 | ADENO-ASSOCIATED VIRUS VARIANT | February 2025 | August 2025 | Allow | 6 | 1 | 1 | No | No |
| 19046064 | SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLES | February 2025 | September 2025 | Allow | 7 | 2 | 0 | No | No |
| 19041480 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | January 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19037555 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODS | January 2025 | January 2026 | Allow | 11 | 1 | 0 | Yes | No |
| 19038526 | SYSTEMS AND METHODS FOR MEASURING CHANGES IN CELLULAR ACTIVITY IN LIVE TISSUE | January 2025 | July 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19035336 | NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE | January 2025 | September 2025 | Allow | 8 | 1 | 1 | No | No |
| 19032762 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | January 2025 | January 2026 | Allow | 12 | 2 | 1 | Yes | No |
| 19031360 | HERPES ZOSTER mRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF | January 2025 | August 2025 | Allow | 7 | 0 | 0 | No | No |
| 18996523 | PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOF | January 2025 | February 2026 | Allow | 13 | 2 | 0 | No | No |
| 19022291 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | January 2025 | May 2025 | Allow | 4 | 0 | 0 | No | No |
| 19022712 | INFLUENZA VACCINE | January 2025 | May 2025 | Allow | 4 | 0 | 0 | No | No |
| 19023243 | NANO FLUORESCENT LATEX PIGMENT WITH HIGH FLUORESCENCE INTENSITY AND HIGH STABILITY AND PREPARATION METHOD THEREFOR | January 2025 | October 2025 | Allow | 9 | 1 | 1 | No | No |
| 19017356 | MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19017195 | ANTI-CD40 SINGLE-DOMAIN ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | January 2025 | January 2026 | Allow | 13 | 1 | 1 | No | No |
| 19014949 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19012978 | VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOF | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18881999 | ANTIBODY, NUCLEIC ACID, CELL, AND PHARMACEUTICAL | January 2025 | February 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 19007447 | METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIER | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 19006818 | METHODS FOR USING DUAL GLYCAN BINDING AAV VECTORS | December 2024 | July 2025 | Allow | 6 | 1 | 1 | No | No |
| 19000472 | BETACORONA VIRUS mRNA VACCINES | December 2024 | June 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 19000377 | BETACORONAVIRUS mRNA VACCINES | December 2024 | December 2025 | Allow | 12 | 1 | 0 | No | No |
| 18989629 | ZIP12 ANTIBODY | December 2024 | July 2025 | Allow | 6 | 0 | 1 | No | No |
| 18984062 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | December 2024 | September 2025 | Allow | 9 | 1 | 0 | No | No |
| 18983037 | METHODS OF TREATING PSORIASIS WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18983034 | METHODS OF TREATING PSORIASIS WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18983030 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASE WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18982853 | PHOSPHORYLATED ANTIGEN AND ANTIBODY AT SER23 SITE OF PGAM1 PROTEIN AS WELL AS PREPARATION METHODS AND APPLICATIONS | December 2024 | August 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18981054 | ANTI-HUMAN NR1 ANTIBODY DERIVATIVE | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18979068 | METHODS FOR TREATING ALZHEIMER'S DISEASE USING SEMAGLUTIDE | December 2024 | September 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18967259 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | December 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18966342 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | December 2024 | January 2026 | Abandon | 14 | 1 | 0 | No | No |
| 18965925 | NANOBODY TARGETING INFLUENZA A VIRUS NUCLEOPROTEIN AND APPLICATION THEREOF, AND NUCLEIC ACID ENCODING NANOBODY | December 2024 | August 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18870747 | HYDROLYZED COLLAGEN FOR USE IN REDUCING BLOOD GLUCOSE | December 2024 | January 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 18964018 | Alpha-herpesvirus Insensitive Monoclonal Cell Strain, and Preparation Method Therefor and Use Thereof | November 2024 | April 2025 | Allow | 4 | 1 | 1 | No | No |
| 18869122 | QUINONE PROTECTED FORMS AND CONJUGATES | November 2024 | February 2026 | Allow | 14 | 1 | 1 | Yes | No |
| 18955996 | METHODS OF ADMINISTERING VITAMIN A AND LACTIC ACID TO GILTS | November 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18955940 | PREPARATION METHOD AND APPLICATION OF NANOBODY TARGETING DENGUE VIRUS NS1 PROTEIN | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18955328 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION BASED ON IMMUNE CHECKPOINT BLOCKADE AND USE THEREOF | November 2024 | January 2026 | Allow | 14 | 3 | 1 | Yes | No |
| 18953973 | ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION | November 2024 | July 2025 | Allow | 8 | 2 | 0 | No | No |
| 18953476 | METHODS FOR PREVENTING AND TREATING BRAIN INFLAMMATION | November 2024 | November 2025 | Allow | 11 | 3 | 0 | Yes | No |
| 18953525 | RECOMBINANT AMEBOCYTE CLOTTING FACTORS AND USES THEREOF | November 2024 | September 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18948648 | INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAME | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18865515 | FUSION PROTEIN AND USE THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 0 | No | No |
| 18941809 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | November 2024 | May 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18941441 | INTERLEUKIN-18 VARIANTS AND METHODS OF USE | November 2024 | December 2025 | Allow | 13 | 2 | 2 | Yes | No |
| 18940501 | ARTIFICIAL RNA MOLECULES ENCODING A NOROVIRUS ANTIGEN AND USES THEREOF | November 2024 | September 2025 | Allow | 10 | 1 | 0 | No | No |
| 18938932 | GALLID ALPHAHERPESVIRUS 3 (MDV-2), A VIRAL VECTOR AGAINST DIFFERENT AVIAN PATHOGENS: A NEW VACCINATION STRATEGY IN THE POULTRY INDUSTRY | November 2024 | April 2025 | Allow | 5 | 0 | 0 | No | No |
| 18936852 | METHODS OF FABRICATING CARRIERS FOR TARGETED DELIVERY TO A HOST | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18934708 | METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS | November 2024 | July 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18861616 | COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISE | October 2024 | June 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18861520 | HYDROGEL COMPOSITION, METHOD FOR PRODUCING THE SAME, AND USE THEREOF FOR STEM CELL MIMETIC PEPTIDE SUPPLEMENTATION | October 2024 | January 2026 | Abandon | 32 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1670.
With a 32.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1670 is part of Technology Center 1600. This group has examined 33,397 patent applications in our dataset, with an overall allowance rate of 73.0%. Applications typically reach final disposition in approximately 29 months.
Applications in Group 1670 receive an average of 1.86 office actions before reaching final disposition. The median prosecution time is 29 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.